BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Abstract Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combinati...

Full description

Bibliographic Details
Main Authors: Salar Farokhi Boroujeni, Galaxia Rodriguez, Kristianne Galpin, Edward Yakubovich, Humaira Murshed, Dalia Ibrahim, Sara Asif, Barbara C. Vanderhyden
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Journal of Ovarian Research
Subjects:
BRCA mutations
Ovarian cancer
PARP inhibitors
Immune checkpoint inhibitors
Online Access:https://doi.org/10.1186/s13048-023-01313-z

Internet

https://doi.org/10.1186/s13048-023-01313-z

Similar Items